Sector News

Roche forms 21-site I/O R&D network, commits $100M

November 17, 2016
Life sciences

Roche has put together a cancer immunotherapy research network and committed up to $100 million to support collaborations between the 21 academic centers. Members of the network will share data, expertise and technology with a view to accelerating the progress of programs out of the lab and into the clinic.

The network, dubbed the global cancer immunotherapy Centers of Research Excellence (imCORE), formalizes the links between Roche, Genentech and the academic centers. Roche is hoping linking and supporting the research sites will lead to new ideas about how to increase the proportion of patients who respond to cancer immunotherapies. So far, the effects of immunotherapies on tumors have ranged from very powerful to non-existent.

Roche is looking outside its walls for help solving the problem.

“We believe the fastest way to advance progress against cancer is through collaboration, and consistent with our values, the goal of imCORE is to facilitate access to new technologies and emerging data among the top researchers around the world,” Roche CMO Dr Sandra Horning said in a statement.

The Swiss Big Pharma is putting up $100 million to support collaborations within the network. That sum, while tiny in the context of Roche’s $8 billion biopharma R&D budget, is meaningful for the type of projects being pursued within imCORE. The sweet spot for the network spans from basic research, through preclinical and into human studies. Roche plans to maximize the bang for its buck by pooling and sharing data generated by imCORE projects.

That approach is in keeping with the prevailing culture in oncology research since the White House’s Cancer Moonshot 2020 program shunted data sharing up the agenda. On paper, the model opens the door to advances downstream of the completion of a study by allowing a network of researchers to bring their own expertise and experience to the data.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach